KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Operations: 2017-2024

Historic Cash from Operations for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$35.8 million.

  • Aquestive Therapeutics' Cash from Operations fell 6.47% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.5 million, marking a year-over-year decrease of 47.47%. This contributed to the annual value of -$35.8 million for FY2024, which is 460.49% down from last year.
  • As of FY2024, Aquestive Therapeutics' Cash from Operations stood at -$35.8 million, which was down 460.49% from -$6.4 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Cash from Operations high stood at -$6.4 million for FY2023, and its period low was -$45.5 million during FY2020.
  • Its 3-year average for Cash from Operations is -$17.3 million, with a median of -$9.8 million in 2022.
  • Per our database at Business Quant, Aquestive Therapeutics' Cash from Operations soared by 70.23% in 2022 and then plummeted by 460.49% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Cash from Operations (Yearly) stood at -$45.5 million in 2020, then climbed by 27.45% to -$33.0 million in 2021, then surged by 70.23% to -$9.8 million in 2022, then soared by 35.02% to -$6.4 million in 2023, then slumped by 460.49% to -$35.8 million in 2024.